The company reported first commercial production and sales of Puratein C canola and FavaPro fava proteins in Q2 fiscal 2025 (period ended September 30, 2025), with expanded production of pea protein. Q2 revenue reached $357,000 with six-month revenue of $699,000, up 152% year-over-year. Burcon is well-positioned in the high-margin plant-protein ingredient market but faces near-term cash constraints as it scales production.
Cyborg Score Rationale
Early commercialization with strong technology portfolio and revenue growth (152% YoY) are positive, but Q2 showed continued significant losses ($7.1M), negative working capital ($8.2M), and only $1.8M cash on hand as of September 2025. The company is dependent on continued financing and customer adoption to reach profitability.
Top Insights
First commercial production and sales of premium ingredients (Puratein C, FavaPro) achieved in Q2 FY2025, validating technology commercialization after two decades of R&D
Revenue growth accelerating (152% H1 YoY) but from a low base ($699K six-month revenue); production capacity expansion underway to meet customer demand
Significant cash burn ($4.6M operating cash used in Q2) and negative working capital ($8.2M) create near-term financing pressure; recent $4M convertible debenture raise and warrant extension sought in February 2026
Competitive market with established players (ADM, Glanbia) but Burcon's proprietary technology and diverse protein portfolio (pea, canola, soy, hemp, fava, sunflower) provide differentiation in high-growth plant-based segment
Named Competitors
Plant-based protein ingredients — Diversified nutrition with commodity plant proteins
Plant-based protein solutions — Specialty ingredients and nutritional solutions
Plant-based proteins — Diversified agriculture with plant-based offerings
Recent Developments
(September 2025) First commercial production and sales of Puratein C canola and FavaPro fava proteins; Q2 revenue $357K, up 783% QoQ; six-month revenue $699K, up 152% YoY
(November 2025) Operational and sales update highlighting plant-protein growth and production achievements
(February 2026) Sought warrant extension to fund plant-protein capacity expansion
Open the full interactive Burcon NutraScience Corporation report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.